Khora Therapeutics

I met the Khora team in 2022 and left the conversation convinced of two things: that they were solving something real, and that Wheelhouse was the right partner to help them say it. I brought them in, and the fit has held through everything that came after.

We started when the company was Shepherd Therapeutics, making an unusual bet for a biotech: speak directly to patients rather than to physicians and clinical stakeholders. Families navigating a rare cancer diagnosis were the audience, and the work had to make an enormously complex subject feel approachable without making it feel small. I led brand strategy alongside our team, which also delivered the visual identity, the website, and the product UI for Delve, their AI platform.

The patient portal came next, and my role expanded into product strategy. Building the thing patients would actually touch is different work than a brand launch. Clinical accuracy and product constraints sit on one side, and on the other is a person receiving hard information on the worst week of their life. Getting those two to agree was most of the job.

Then the company changed underneath the brand. Shepherd became Khora, the business moved into drug development, and the audience shifted again, this time toward investors. I am leading the site rebuild now, with a different job to do than either version before it: making the case for their next round of funding.

Three business models, three audiences, one partner throughout. Our team moves quickly on each new phase because we already understand the science, the constraints, and how this company talks about itself. Holding that context across four years is what has kept Wheelhouse in the room. It helps that the Khora team has been a genuine pleasure to work with, and that their mission is one I care about well beyond the scope of the work.